Skip to main content
. Author manuscript; available in PMC: 2019 Oct 1.
Published in final edited form as: Clin Cancer Res. 2018 Dec 18;25(7):2323–2335. doi: 10.1158/1078-0432.CCR-18-0959

Figure 2. Knockdown of RANBP2 inhibits growth and survival of cells expressing JAK2V617F.

Figure 2.

HEL cells (A, B) and SET-2 cells (C, D) were engineered to express doxycycline (Dox)-inducible shRNAs specifically targeting RANBP2. RANBP2 expression was assessed by immunoblot (A, C) at 72 hours after adding Dox. Effects of RANBP2 knockdown were measured by viable cell counting (B, D). Data are from two to three independent experiments.

*p<0.01, *p<0.001